NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.59 +0.05 (+3.25 %) (As of 05/26/2019 04:00 PM ET)Previous Close$1.59Today's Range$1.57 - $1.6152-Week Range$1.25 - $3.90Volume73,428 shsAverage Volume85,245 shsMarket Capitalization$107.60 millionP/E RatioN/ADividend YieldN/ABeta1.93 ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas. Receive NYMX News and Ratings via Email Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NYMX Previous Symbol CUSIPN/A CIK1018735 Webhttp://www.nymox.com/ Phone800-936-9669Debt Debt-to-Equity Ratio0.03 Current Ratio8.04 Quick Ratio8.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$300,000.00 Price / Sales358.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book10.60Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,590,000.00 Net Margins-6,101.69% Return on Equity-175.82% Return on Assets-144.94%Miscellaneous EmployeesN/A Outstanding Shares67,676,000Market Cap$107.60 million Next Earnings Date8/12/2019 (Estimated) OptionableOptionable Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions What is Nymox Pharmaceutical's stock symbol? Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX." How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Corp (NASDAQ:NYMX) announced its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.03 million for the quarter. Nymox Pharmaceutical had a negative return on equity of 175.82% and a negative net margin of 6,101.69%. View Nymox Pharmaceutical's Earnings History. When is Nymox Pharmaceutical's next earnings date? Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Nymox Pharmaceutical. Has Nymox Pharmaceutical been receiving favorable news coverage? News articles about NYMX stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nymox Pharmaceutical earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Nymox Pharmaceutical's key competitors? Some companies that are related to Nymox Pharmaceutical include Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ). What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Synergy Pharmaceuticals (SGYP), Biocept (BIOC), TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), Catalyst Pharmaceuticals (CPRX), CTI BioPharma (CTIC), MEI Pharma (MEIP) and Novavax (NVAX). Who are Nymox Pharmaceutical's key executives? Nymox Pharmaceutical's management team includes the folowing people: Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)Mr. Erik Danielsen, Chief Financial Officer (Age 56)Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55) Who are Nymox Pharmaceutical's major shareholders? Nymox Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.43%), Wedbush Securities Inc. (0.17%), Morgan Stanley (0.12%), Parametric Portfolio Associates LLC (0.09%), State of Wisconsin Investment Board (0.07%) and Willow Creek Wealth Management Inc. (0.05%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical. Which institutional investors are selling Nymox Pharmaceutical stock? NYMX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Wedbush Securities Inc. and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Nymox Pharmaceutical. Which institutional investors are buying Nymox Pharmaceutical stock? NYMX stock was bought by a variety of institutional investors in the last quarter, including Willow Creek Wealth Management Inc., State of Wisconsin Investment Board and BlackRock Inc.. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson and Randall J Lanham. View Insider Buying and Selling for Nymox Pharmaceutical. How do I buy shares of Nymox Pharmaceutical? Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nymox Pharmaceutical's stock price today? One share of NYMX stock can currently be purchased for approximately $1.59. How big of a company is Nymox Pharmaceutical? Nymox Pharmaceutical has a market capitalization of $107.60 million and generates $300,000.00 in revenue each year. What is Nymox Pharmaceutical's official website? The official website for Nymox Pharmaceutical is http://www.nymox.com/. How can I contact Nymox Pharmaceutical? Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected] MarketBeat Community Rating for Nymox Pharmaceutical (NASDAQ NYMX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 101 (Vote Outperform)Underperform Votes: 103 (Vote Underperform)Total Votes: 204MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What defines an oversold asset? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.